F J Giles
Overview
Explore the profile of F J Giles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
2520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carneiro B, Collier K, Nagy R, Pamarthy S, Sagar V, Fairclough S, et al.
JCO Precis Oncol
. 2019 Sep;
2.
PMID: 31501807
PARP1/2 inhibitors are effective against BRCA2-deficient tumors. The PARP inhibitor (PARPi) olaparib received FDA breakthrough designation for treatment of metastatic castration-resistant prostate cancers (CRPC) carrying mutations in or genes. Emergent...
2.
Florek A, Nardone B, Thareja S, Tran G, Giles F, West D
Br J Dermatol
. 2017 Jun;
177(5):e220-e221.
PMID: 28646575
No abstract available.
3.
Costa R, Gill N, Rademaker A, Carneiro B, Chae Y, Kumthekar P, et al.
Cancer Treat Rev
. 2017 Mar;
55:10-15.
PMID: 28279895
Purpose: This systematic review aims to better define the limitations and patterns with which patients with MBC and CNS metastasis are enrolled into early phase developmental therapeutics trials. Methods: In...
4.
Hochhaus A, Masszi T, Giles F, Radich J, Ross D, Gomez Casares M, et al.
Leukemia
. 2017 Feb;
31(7):1525-1531.
PMID: 28218239
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with...
5.
Costa R, Carneiro B, Wainwright D, Santa-Maria C, Kumthekar P, Chae Y, et al.
Ann Oncol
. 2017 Feb;
28(1):44-56.
PMID: 28177431
Breast cancer is the second-leading cause of metastatic disease in the central nervous system (CNS). Recent advances in the biological understanding of breast cancer have facilitated an unprecedented increase of...
6.
Swords R, Watts J, Erba H, Altman J, Maris M, Anwer F, et al.
Blood Cancer J
. 2017 Feb;
7(2):e520.
PMID: 28157218
No abstract available.
7.
Giles F, Lord C, Gaminarai E, Grants I, Kearney J, Mills M, et al.
Leuk Lymphoma
. 2016 Jul;
1(3-4):227-33.
PMID: 27463990
The pattern of disease relapse in nine patients with multiple myeloma who had received double hemi body irradiation therapy is analysed. This analysis highlights the localisation of these relapses to...
8.
Giles F, Anderson C, Grant I, Hoffbrand A, Mehta A, Machin S, et al.
Leuk Lymphoma
. 2016 Jul;
3(2):103-7.
PMID: 27457295
Recombinant alpha 2a, 2b and 2c interferons have been shown to be effective short-term agents in essential thrombocythaemia and thrombocythaemia associated with the other myeloproliferative disorders, including chronic granulocytic leukaemia,...
9.
Lynott A, Ravandi-Kashani F, Giles F
Hematology
. 2016 Jul;
4(6):487-93.
PMID: 27420743
Conditions associated with increased peripheral blood and bone marrow eosinophil count may be reactive, clonal or idiopathic. Clonal eosinophilic disorders are characterized by increased production of eosinophils alongside a clone...
10.
Ravandi-Kashani F, Sriswasdi C, Lynott A, Giles F
Hematology
. 2016 Jul;
3(6):429-41.
PMID: 27420330
Infection with the human T-lymphotropic virus type 1 (HTLV-1) has been shown to be fundamental to the etiology of Adult T-cell Leukemia/Lymphoma (ATL). The disease is endemic in specific geographic...